Abattis Bioceuticals Corp (ATTBF) is a Canadian company focusing on the biotechnology, licensing, cultivation, and distribution of cannabis products. Aiming to be a player in the marijuana markets in Canada and the US, the company operates through subsidiaries and with partners in the industry.
Incorporated in 1997, Abattis Bioceuticals was formerly known as Abattis Biologix Corp until it changed to its current name in 2012. It is now traded in OTC markets as ATTBF, having a market cap of USD 14.55 M.
There are five featured subsidiaries of the company: Biocube Green Grow Systems Corp; Biocell Labs, Inc; iJuana Cannabis, Inc; North America Bioextracts; and Northern Vine Canada, Inc.
Biocube Green Grow Systems Corp is a provider of controlled cultivation environments. One of its primary products is the MgO board, a building material with many benefits and to which Biocube owns exclusive rights.
Biocell Labs, Inc is the Abattis subsidiary that supplies proprietary cannabis formulations for pharmaceutical, nutraceutical, and cosmetic products.
iJuana Cannabis, Inc meanwhile grows cannabis in a 27,000-square foot facility in Squamish, BC. It will also serve as the company’s end-consumer representative.
North America Bioextracts, which has offices in Washington State and Canada, develops and retails end-user cannabis products such as extract oils and vaporizer flavors.
Finally, Northern Vine Canada, Inc processes, tests, and packages marijuana, as well as provides analytical services, in the company’s Langley, BC facility.
Abattis Bioceuticals’ partners include the testing firm PhytaLab, the cannabis strain developer Experion Bio Technologies, Inc, and the transactions technology provider Instant Payment Systems.
The top management team at Abattis is comprised of Michael Withrow, Chairman, CEO, and President; Rene David, CFO and COO; Jason Anderson, VP of Finance; and Gilbert G. Schneider, Consultant.
Yahoo! Finance: ATTBF News
Latest Financial News for ATTBF
Abattis Bioceuticals Corp (the “Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to announce that, further to its news release dated April 2nd, 2019, the Company’s wholly-owned subsidiary, 1185277 B.C. Ltd. (the “Acquisition Subsidiary”) has successfully closed the acquisition (the “Acquisition”) of Pro Natura BV (“Pro Natura”). Abattis is also pleased to announce that it will be relaunching its Company Newsletter (the “Newsletter”), which has been designed to complement the Company’s continuous disclosure, and provide cannabis industry highlights as they pertain to the Company.
VANCOUVER, British Columbia, April 2, 2019 /PRNewswire/ -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (ATT.CN) (ATTBF) is pleased to announce that its wholly-owned subsidiary, 1185277 B.C. Ltd. (the "Acquisition Subsidiary"), has entered into a share purchase agreement (the "Agreement") to acquire (the "Acquisition") Pro Natura BV ("Pro Natura"), a privately held nutraceutical company based in Oisterwijk, Netherlands. Pro Natura has over 30 years of operations and sales experience in Europe, with over 100 products that have been marketed to both long-term repeat customers and new large groups of distributors. Pro Natura has been supported by a seasoned management team that still includes its original founder and has historically boasted €10M+ in per annum sales.
Vancouver, British Columbia--(Newsfile Corp. - March 9, 2019) - Abattis Bioceuticals Corp (CSE: ATT) (OTC Pink: ATTBF) (the "Company" or "Abattis") announces that, effective February 20, 2019 and March 6, 2019, both Wolfgang Richter and James Irving have respectively resigned as directors of the Company.The Company thanks both Mr. Richter and Mr. Irving for their service and wishes each all the best in their future endeavors.About Abattis Bioceuticals Corp.Abattis is positioned to be ...
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) provides the following update on the Company’s recent trading halt and upcoming conference call with Company management that was previously set for March 1, 2019. Further to the Company’s news release dated February 18, 2019, trading of the Company’s common shares continues to be halted on the Canadian Securities Exchange until the Company files its financial statements for the year ended September 30, 2018 (the “Financials”).
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to provide the following update on the Company’s recent trading halt and upcoming conference call with Company management set for March 1, 2019. On February 4, 2019, the trading of the Company’s common shares was halted due to the Company’s failure to file its year-end financial statements within the 90 day filing deadline required under National Instrument 51-102 – Continuous Disclosure Requirements. The Company is still undergoing its year-end financial statement audit and believes it will have them filed in the coming week.